- Report
- March 2025
- 250 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- October 2024
- 198 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- October 2024
- 180 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- November 2024
- 100 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- July 2024
- 150 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- January 2025
- 375 Pages
Global
From €4551EUR$5,000USD£3,901GBP
- Report
- April 2025
- 250 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 250 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 175 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- November 2024
- 150 Pages
Global
From €4414EUR$4,850USD£3,784GBP
- Report
- April 2025
- 175 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- July 2024
- 136 Pages
Global
From €2729EUR$2,999USD£2,340GBP
- Report
- May 2024
- 137 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3413EUR$3,750USD£2,926GBP
- Report
- April 2025
- 200 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- December 2024
- 200 Pages
Global
From €3413EUR$3,750USD£2,926GBP

Infliximab is a monoclonal antibody used to treat a variety of immune disorders, including Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. It works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Infliximab is administered intravenously and is usually given in combination with other medications. It is also used to treat certain types of eye inflammation and to prevent organ rejection in transplant patients.
Infliximab is a biologic drug, meaning it is derived from living cells. It is produced by a number of pharmaceutical companies, including Merck, Pfizer, and Janssen. It is available in both brand-name and generic forms.
The companies in the Infliximab market include Merck, Pfizer, Janssen, Celltrion, Hospira, and Sandoz. Show Less Read more